CMR of Greater New Haven, LLC

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes7 trials
• Obesity5 trials
• Chronic kidney disease2 trials
• Colorectal cancer1 trial
• High blood pressure1 trial
• Migraine1 trial
• Osteoarthritis1 trial
• Type 1 diabetes1 trial

Phase

• Phase 310 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Completed6 trials
• Recruiting4 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company8 trials
• Boehringer Ingelheim2 trials
• Guardant Health, Inc.1 trial
• Hoffmann-La Roche1 trial
• Pfizer1 trial

Running trials

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

  NCT07843498· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  NCT07282600· Phase 3· Eli Lilly and Company· Source

  Contact: Jillian Reid (principal investigator)

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

  NCT06859268· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

  NCT05986292· Phase 2· Eli Lilly and Company· Source

  Contact: Jillian Reid (principal investigator)

• Active, not recruiting

  Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

  NCT04136002· Guardant Health, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Type 2 diabetes2 recruiting
• High blood pressure1 recruiting
• Osteoarthritis1 recruiting

Closed trials

• Completed

  A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

  NCT06192108· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

  NCT06109311· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

  NCT05462756· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Pfizer· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source